5-HT1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 86-91

  Shimizu, Saki ^a   Mizuguchi, Yuto ^a   Tatara, Ayaka ^a   Kizu, Tomoya ^a   Andatsu, Saki ^a   Sobue, Akira ^a   Fujiwara, Mai ^a   Morimoto, Tomoki ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

5 HT1A agonists; Antidepressants; Antipsychotics; Extrapyramidal symptoms; Microinjection; Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; FLUOXETINE; HALOPERIDOL; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; ANTIDEPRESSANT AGENT; SECOND GENERATION ANTIPSYCHOTIC; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DORSOLATERAL STRIATUM; DOSE RESPONSE; DRUG MECHANISM; EXTRAPYRAMIDAL SYNDROME; MALE; MEDIAN RAPHE NUCLEUS; MICROINJECTION; MOTOR CORTEX; MOUSE; NERVOUS SYSTEM PARAMETERS; NEUROMODULATION; NONHUMAN; RAT; SEROTONERGIC POTENTIATION; SEROTONINERGIC SYSTEM; ANIMAL; BASAL GANGLIA DISEASES; BRAIN; DRUG EFFECTS; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; (±)-8-HYDROXY-2-(DI-N-PROPYLAMINO) TETRALIN; (±)-8-OH-DPAT; 5-HT(1A) AGONISTS; ANTIPSYCHOTICS; DLST; DRUG EFFECT; EPS; EXTRAPYRAMIDAL SYMPTOMS; MC; METHODOLOGY; MRN; SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI); SGA;

ANIMALS; BASAL GANGLIA DISEASES; BRAIN; MALE; MICE; MICROINJECTIONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

(±)-8-HYDROXY-2-(DI-N-PROPYLAMINO) TETRALIN; (±)-8-OH-DPAT; 5-HT(1A) AGONISTS; ANTIDEPRESSANTS; ANTIPSYCHOTICS; DLST; DORSOLATERAL STRIATUM; EPS; EXTRAPYRAMIDAL SYMPTOMS; MC; MEDIAL RAPHE NUCLEUS; MICROINJECTION; MOTOR CORTEX; MRN; SECOND GENERATION ANTIPSYCHOTIC; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI); SGA; SSRI;

EID: 84880961424     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.06.016     Document Type: Article

References (52)

1. Akimova E., Lanzenberger R., Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009, 66:627-635.
2. Appelberg B.G., Syvälahti E.K., Koskinen T.E., Mehtonen O.P., Muhonen T.T., Naukkarinen H.H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001, 62:448-452.
3. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
4. Baumgarten H.G., Grozdanovic Z. Psychopharmacology of central serotonergic systems. Pharmacopsychiatry 1995, 2:73-79.
5. 1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53:193-203.
6. Chartoff E.H., Ward R.P., Dorsa D.M. Role of adenosine and N-methyl-d-aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 1999, 291:531-537.
7. de Montigny C., Chaput Y., Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990, 51:4-8.
8. el Mansari M., Blier P. In vivo electrophysiological characterization of 5-HT receptors in the Guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology 1997, 36(4-5):577-588.
9. Feighner J.P., Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 1989, 22(Suppl. 1):21-26.
10. Fuller R.W. Role of serotonin in therapy of depression and related disorders. J Clin Psychiatry 1991, 52:52-57.
11. Hadrava V., Blier P., Dennis T., Ortemann C., de Montigny C. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study. Neuropharmacology 1995, 34(10):1311-1326.
12. Hajós M., Gartside S.E., Sharp T. Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn Schmiedebergs Arch Pharmacol 1995, 351(6):624-629.
13. 7 receptors to induce hypothermia in rodents. Eur J Pharmacol 2004, 487:125-132.
14. Hirose A., Sasa M., Akaike A., Takaori S. Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997. Neuropharmacology 1990, 29(2):93-101.
15. Hussain N., Flumerfelt B.A., Rajakumar N. Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 2001, 102:391-399.
16. Invernizzi R.W., Cervo L., Samanin R. 8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis. Neuropharmacology 1988, 27:515-518.
17. 1A agonist, tandospirone, in rats. Biog Amines 2004, 8:329-338.
18. Kapur S., Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001, 52:503-517.
19. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991, 17(2):263-287.
20. 1A receptors improve cognition in schizophrenia?. Behav Brain Res 2008, 195(1):98-102.
21. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27(7):1159-1172.
22. 1A receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl) 2002, 163(1):85-94.
23. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993, 265(1):207-217.
24. 1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010, 11:802-812.
25. 1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci Ther 2011, 17:58-65.
26. 1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(5):1302-1307.
27. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., et al. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 2008, 55(5):717-723.
28. 1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci 2009, 109(4):593-599.
29. 6 receptors. Neuropharmacology 2011, 60(2-3):201-208.
30. Ohno Y., Tatara A., Shimizu S., Sasa M. Management of cognitive impairments in schizophrenia: the therapeutic role of 5-HT receptors. Antipsychotic drugs: pharmacology, side effects and abuse prevention 2012, 323-338. Nova Science Publishers, Inc., NY. T. Sumiyoshi (Ed.).
31. Ohno Y., Shimizu S., Imaki J., Masui A., Tatara A. Management of antipsychotic-induced extrapyramidal motor disorders: regulatory roles of the serotonergic nervous system. Antipsychotic drugs: pharmacology, side effects and abuse prevention 2013, 219-234. Nova Science Publishers, Inc., NY. T.L. Schwartz, M. Topel, J.L. Menga (Eds.).
32. Paez X., Leibowitz S.F. Changes in extracellular PVN monoamines and macronutrient intake after idazoxan or fluoxetine injection. Pharmacol Biochem Behav 1993, 46(4):933-941.
33. Papakostas G.I., Petersen T.J., Nierenberg A.A., Murakami J.L., Alpert J.E., Rosenbaum J.F., et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004, 65(2):217-221.
34. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Elsevier, Manhattan. 6th ed.
35. Perry K.W., Fuller R.W. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid rat striatum. Life Sci 1992, 50(22):1683-1690.
36. 1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002, 453(2-3):217-221.
37. Pucadyil T.J., Kalipatnapu S., Chattopadhyay A. The serotonin1A receptor: a representative member of the serotonin receptor family. Cell Mol Neurobiol 2005, 25:553-580.
38. 1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 1999, 127(8):1751-1764.
39. Roth B.L. Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry 1994, 6:67-78.
40. Sato Y., Yasui-Furukori N., Nakagami T., Saito M., Kaneko S. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(3):416-418.
41. 1A receptors. Aging Dis 2013, 4(1):1-13.
42. 1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(6):877-881.
43. Shimizu S., Mizuguchi Y., Ohno Y. Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Disord Drug Targets 2013, 12(8).
44. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol 2000, 163:239-243.
45. Sumiyoshi T., Bubenikova-Valesova V., Horacek J., Bert B. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 2008, 25(10):1037-1056.
46. Tada K., Kasamo K., Ueda N., Suzuki T., Kojima T., Ishikawa K. Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. J Pharmacol Exp Ther 1999, 288(2):843-848.
47. Tatara A., Shimizu S., Shin N., Sato M., Sugiuchi T., Imaki J., et al. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38(2):252-259.
48. 1A receptor ligands on rat dorso-lateral septal neurones in vitro. Br J Pharmacol 1992, 106(4):893-899.
49. 1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat. Neuropharmacology 1995, 34:495-499.
50. Wadenberg M.L., Young K.A., Richter J.T., Hicks P.B. Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat. Neuropharmacology 1999, 38(1):151-156.
51. Yanahashi S., Hashimoto K., Hattori K., Yuasa S., Iyo M. Role of NMDA receptor subtypes in the induction of catalepsy and increase in Fos protein expression after administration of haloperidol. Brain Res 2004, 1011:84-93.
52. 1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology 2006, 51(1):129-140.